(Gastric Cancer) Nivolumab (Opdivo) Plus Ramucirumab (Cyramza) as Second-Line Therapy: NivoRam Phase 1/2 Study

• March 13, 2019
• 1 min read

At the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2019), held in San Francisco from January 17–19, 2019, results from a Phase 1/2 clinical trial evaluating nivolumab (anti-PD-1 antibody) plus ramucirumab (anti-VEGF antibody) combination therapy as second-line treatment for advanced gastric cancer were presented.

The 6-month progression-free rate for this combination as second-line therapy in advanced gastric cancer patients was 37.4%.

Dr. Hiroki Hara analyzed the results and concluded that patients showed good tolerability to adverse events and favorable anti-tumor activity with this combination regimen.

Source: Phase I/II study of ramucirumab plus nivolumab in patients in second line treatment for advanced gastric adenocarcinoma (NivoRam study). ASCO-GI 2019, Abstract 129.

Gastric Cancer | Nivolumab | Ramucirumab | Second-Line Therapy

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1